# Biotech Daily Digest — 2026-01-20

**12 items from 3 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 6 items
- Fierce Biotech: 5 items


## Eli Lilly Press Releases

- **[Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer](https://investor.lilly.com/news-releases/news-release-details/lillys-sofetabart-mipitecan-receives-us-fdas-breakthrough)**  
  _Tue, 20 Jan 2026 07:45:00 -0500_  
  INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial


## Endpoints News

- **[2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons](https://endpoints.news/2025-ended-on-high-note-with-a-buoyant-q4-for-ma-pipes-and-follow-ons/)**  
  _Tue, 20 Jan 2026 13:00:25 +0000_  
  After a downbeat start to 2025, biopharma struck some high notes in the second half and ended the year with strong Q4 momentum in dealmaking, fundraising and M&A. The numbers, once again tracked for us ...

- **[Pfizer to depart GSK's ViiV as Shionogi doubles its stake](https://endpoints.news/pfizer-to-depart-gsks-viiv-as-shionogi-doubles-its-stake/)**  
  _Tue, 20 Jan 2026 12:02:06 +0000_  
  Pfizer is walking away from a specialist HIV company it created together with GSK more than a decade ago, with Shionogi taking its place.

 The Japanese drugmaker will buy about $2.13 billion worth of new ...

- **[Corvus' new Phase 1 atopic dermatitis data meet high expectations](https://endpoints.news/corvus-new-phase-1-atopic-dermatitis-data-meet-high-expectations/)**  
  _Tue, 20 Jan 2026 12:00:19 +0000_  
  Corvus Pharmaceuticals’ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts' best-case scenario.

 The company's share price {$CRVS} jumped as ...

- **[J&J, Isomorphic sign research deal for AI-made molecules](https://endpoints.news/jj-isomorphic-sign-research-deal-for-ai-made-molecules/)**  
  _Tue, 20 Jan 2026 12:00:09 +0000_  
  The Google DeepMind spinout Isomorphic Labs has landed its third pharma deal.

 The AI-focused biotech has signed a multi-target research deal with Johnson & Johnson, the two companies announced Tuesday. Isomorphic, founded in 2021 and ...

- **[GSK makes $2.2B deal for RAPT and its food allergy candidate](https://endpoints.news/gsk-makes-2-2b-deal-for-rapt-and-its-food-allergy-candidate/)**  
  _Tue, 20 Jan 2026 10:34:11 +0000_  
  The biopharma industry was hungry for an M&A deal during last week’s JP Morgan Healthcare Conference.

 It's finally getting one.

 GSK is scooping up RAPT Therapeutics for $2.2 billion, with a $1.9 billion upfront investment ...

- **[Exciva raises $59M Series B to fund Phase 2 test of Alzheimer’s agitation drug](https://endpoints.news/exciva-raises-59m-series-b-to-fund-phase-2-test-of-alzheimers-agitation-drug/)**  
  _Tue, 20 Jan 2026 06:30:30 +0000_  
  Exciva has secured €51 million ($59 million) in a Series B raise to advance its candidate for a common behavioral symptom of Alzheimer’s disease into mid-stage development.



 The German biotech will use the proceeds to ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/boundless-finally-gives-combo-treatment-2-unimpressive-cancer-drugs" hreflang="en">Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs </a>](https://www.fiercebiotech.com/biotech/boundless-finally-gives-combo-treatment-2-unimpressive-cancer-drugs)**  
  _Jan 20, 2026 8:31am_  
  Boundless Bio has finally given up on its hopes of finding redemption for two solid tumor drugs that had both come up short in the clinic by packaging them up as a combination treatment.

- **[<a href="https://www.fiercebiotech.com/biotech/merck-moderna-cancer-vaccine-sustains-49-melanoma-risk-reduction-5-years" hreflang="en">Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years</a>](https://www.fiercebiotech.com/biotech/merck-moderna-cancer-vaccine-sustains-49-melanoma-risk-reduction-5-years)**  
  _Jan 20, 2026 7:51am_  
  Adding Merck & Co. and Moderna’s vaccine candidate to Keytruda has continued to cut the risk of cancer recurrence or death across five years of follow-up, boosting the companies’ prospects as they close in on phase 3 data.

- **[<a href="https://www.fiercebiotech.com/biotech/gsk-pays-22b-buy-rapt-its-phase-2-stage-food-allergy-challenger-xolair" hreflang="en">GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair</a>](https://www.fiercebiotech.com/biotech/gsk-pays-22b-buy-rapt-its-phase-2-stage-food-allergy-challenger-xolair)**  
  _Jan 20, 2026 4:38am_  
  GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.

- **[<a href="https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t" hreflang="en">AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta</a>](https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t)**  
  _Jan 19, 2026 10:37am_  
  The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s own GPC3-targeting CAR-T.

- **[<a href="https://www.fiercebiotech.com/medtech/guardant-health-pens-merck-co-cancer-collab-next-gen-tests-and-companion-diagnostics" hreflang="en">Guardant Health pens Merck &amp; Co. cancer collab for next-gen tests, companion diagnostics </a>](https://www.fiercebiotech.com/medtech/guardant-health-pens-merck-co-cancer-collab-next-gen-tests-and-companion-diagnostics)**  
  _Jan 19, 2026 8:49am_  
  Guardant Health is signing up to a multiyear deal with Merck & Co. for the U.S. Big Pharma to tap its Infinity Smart platform.
